keyword
MENU ▼
Read by QxMD icon Read
search

Ivabradine AND Heart failure

keyword
https://www.readbyqxmd.com/read/29777284/current-drug-therapy-for-heart-failure-with-reduced-ejection-fraction
#1
D Berliner, M Hallbaum, J Bauersachs
The prevalence of heart failure has been steadily increasing during the past few years, with a further increase predicted in the years to come. Without treatment, the syndrome of heart failure has a very poor prognosis. Advances in drug treatments and the consequent implementation of a guideline-recommended drug therapy have significantly improved the prognosis in heart failure with reduced ejection fraction (HFrEF). Besides angiotensin-converting enzyme (ACE) inhibitors (ACEi) or angiotensin receptor blockers, beta-blockers and diuretics treatment with mineralocorticoid receptor antagonists and ivabradine have become standard in the therapy of symptomatic patients with HFrEF...
May 18, 2018: Herz
https://www.readbyqxmd.com/read/29762337/real-life-indications-to-ivabradine-treatment-for-heart-rate-optimization-in-patients-with-chronic-systolic-heart-failure
#2
Lara Tondi, Gabriele Fragasso, Roberto Spoladore, Giuseppe Pinto, Marco Gemma, Massimo Slavich, Cosmo Godino, Anna Salerno, Claudia Montanaro, Alberto Margonato
: Ivabradine is a selective and specific inhibitor of If current. With its pure negative chronotropic action, it is recommended by European Society of Cardiology and American College of Cardiology/American Heart Association guidelines in symptomatic heart failure patients (NYHA ≥ 2) with ejection fraction 35% or less, sinus rhythm and heart rate (HR) at least 70 bpm, despite maximally titrated β-blocker therapy. Data supporting this indication mainly derive from the SHIFT study, in which ivabradine reduced the combined endpoint of mortality and hospitalization, despite the fact that only 26% of patients enrolled were on optimal β-blocker doses...
May 11, 2018: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/29761293/stable-but-progressive-nature-of-heart-failure-considerations-for-primary-care-physicians
#3
REVIEW
Inder Anand
Primary care physicians play a significant role in managing heart failure (HF), with the goals of reducing mortality, avoiding hospitalization, and improving patients' quality of life. Most HF-related hospitalizations and deaths occur in patients with New York Heart Association functional class II or III, many of whom are perceived to have stable disease, which often progresses without clinical symptoms due to underlying deleterious effects of neurohormonal imbalance and endothelial dysfunction. Management includes lifestyle changes and stepped pharmacological therapy directed at the four stages of HF, with aggressive uptitration of therapies, including beta-blockers and inhibitors of the renin-angiotensin-aldosterone system...
May 14, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29744528/device-therapy-in-heart-failure-with-reduced-ejection-fraction-cardiac-resynchronization-therapy-and-more
#4
D Duncker, C Veltmann
In patients with heart failure with reduced ejection fraction (HFrEF), optimal medical treatment includes beta-blockers, ACE inhibitors/angiotensinreceptor-neprilysin inhibitors (ARNI), mineralocorticoid receptor antagonists, and ivabradine when indicated. In device therapy of HFrEF, implantable cardioverter-defibrillators and cardiac resynchronization therapy (CRT) have been established for many years. CRT is the therapy of choice (class I indication) in symptomatic patients with HFrEF and a broad QRS complex with a left bundle branch block (LBBB) morphology...
May 9, 2018: Herz
https://www.readbyqxmd.com/read/29738373/ivabradine-s-pleiotropic-profile-can-it-protect-against-doxorubicin-induced-heart-failure
#5
Richard L Verrier
No abstract text is available yet for this article.
May 3, 2018: Journal of Cardiovascular Pharmacology
https://www.readbyqxmd.com/read/29716702/heart-rate-manipulation-in-dilated-cardiomyopathy-assessing-the-role-of-ivabradine
#6
Deep Chandh Raja, Aditya Kapoor, Archana Sinha, Shiridhar Kashyap, Roopali Khanna, Sudeep Kumar, Naveen Garg, Satyendra Tewari, Pravin Goel
BACKGROUND: Heart rate (HR) reduction is of benefit in chronic heart failure (HF). The effect of heart rate reduction using Ivabradine on various echocardiographic parameters in dilated cardiomyopathy has been less investigated. METHODS: Of 187 patients with HF (DCM, NYHA II-IV, baseline HR>70/min), 125 patients were randomized to standard therapy (beta blockers, ACEI, diuretics, n=62) or add-on Ivabradine (titrated to maximum 7.5mg BD, n=63). Beta-blockers were titrated in both the groups...
March 2018: Indian Heart Journal
https://www.readbyqxmd.com/read/29716694/adding-ivabradine-to-beta-blockers-in-chronic-heart-failure-do-not-rest-without-lowering-the-resting-heart-rate-sufficiently
#7
EDITORIAL
Abraham Oomman, Manish Bansal
No abstract text is available yet for this article.
March 2018: Indian Heart Journal
https://www.readbyqxmd.com/read/29688913/the-possible-ameliorative-effect-of-ivabradine-on-the-autonomic-and-left-ventricular-dysfunction-induced-by-doxorubicin-in-male-rats
#8
Amany E El-Naggar, Sahar M El-Gowilly, Fouad M Sharabi
Heart failure is a common adverse effect associated with doxorubicin treatment. The aim of this study is to investigate the effect of ivabradine treatment on doxorubicin-induced heart failure in conscious rats. Rats were treated with doxorubicin (2.5 mg/kg/day) or ivabradine (10 mg/kg/day) alone or along with doxorubicin injections. Changes in heart rate variability (HRV), baroreflex sensitivity, left ventricular function, serum cardiac troponin T and cardiac histological features were taken as index parameters for the development of heart failure...
April 20, 2018: Journal of Cardiovascular Pharmacology
https://www.readbyqxmd.com/read/29687317/the-effects-of-heart-rate-control-in-chronic-heart-failure-with-reduced-ejection-fraction
#9
REVIEW
Dario Grande, Massimo Iacoviello, Nadia Aspromonte
Elevated heart rate has been associated with worse prognosis both in the general population and in patients with heart failure. Heart rate is finely modulated by neurohormonal signals and it reflects the balance between the sympathetic and the parasympathetic limbs of the autonomic nervous system. For this reason, elevated heart rate in heart failure has been considered an epiphenomenon of the sympathetic hyperactivation during heart failure. However, experimental and clinical evidence suggests that high heart rate could have a direct pathogenetic role...
April 23, 2018: Heart Failure Reviews
https://www.readbyqxmd.com/read/29667019/what-is-new-in-heart-failure-management-in-2017-update-on-acc-aha-heart-failure-guidelines
#10
REVIEW
Biykem Bozkurt
PURPOSE OF REVIEW: The goal of this paper is to provide a summary of the new recommendations in the most recent 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. The intent is to provide the background and the supporting evidence for the recommendations and to provide practical guidance for management strategies in treatment of heart failure patients...
April 17, 2018: Current Cardiology Reports
https://www.readbyqxmd.com/read/29622423/optimization-of-heart-rate-lowering-therapy-in-hospitalized-patients-with-heart-failure-insights-from-the-optimize-heart-failure-care-program
#11
Yuri M Lopatin, Martin R Cowie, Anna A Grebennikova, Hamayak S Sisakian, Zurab M Pagava, Hamlet G Hayrapetyan, Timur A Abdullaev, Leonid G Voronkov, Anna I Chesnikova, Vira I Tseluyko, Ekaterina I Tarlovskaya, Gülnaz M Dadashova, Salim F Berkinbaev, Maria G Glezer, Natalia A Koziolova, Amina G Rakisheva, Zviad V Kipiani, Alena K Kurlyanskaya
BACKGROUND: Hospitalization is an opportunity to optimize heart failure (HF) therapy. As optimal treatment for hospitalized HF patients in sinus rhythm with heart rate≥70bpm is unclear, we investigated the impact of combined beta-blocker (BB) and ivabradine versus BBs alone on short and longer term mortality and rehospitalization. METHODS AND RESULTS: A retrospective analysis was performed on 370 hospitalized HF patients with heart rate≥70bpm (150 BB+ivabradine, 220 BB alone) in the Optimize Heart Failure Care Program in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Russia, Ukraine, and Uzbekistan, from October 2015 to April 2016...
June 1, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29621054/the-importance-of-heart-rate-in-heart-failure-and-reduced-ejection-fraction
#12
Marilyn A Prasun, Nancy M Albert
BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) is a progressive, chronic, and burdensome cardiovascular condition. It is associated with limiting symptoms, such as dyspnea and fatigue; a decline in functional capacity; and premature mortality and hospitalization. In heart failure (HF) management, heart rate is commonly assessed yet frequently overlooked as a modifiable risk factor and a predictor of mortality. An elevated heart rate increases myocardial demand and decreases diastolic filling time...
April 4, 2018: Journal of Cardiovascular Nursing
https://www.readbyqxmd.com/read/29594814/novel-drugs-for-heart-rate-control-in-heart-failure
#13
REVIEW
Agata Bielecka-Dabrowa, Stephan von Haehling, Jacek Rysz, Maciej Banach
In patients with heart failure, increased sympathetic activity is associated with a positive chronotropic stimulation leading to accelerated resting heart rate. Elevated heart rate (HR) is a risk factor for cardiovascular events, both in the general population and in patients with heart failure. Ivabradine is a pure HR-lowering agent, and it does not affect myocardial contractility, blood pressure, intracardiac conduction, or ventricular repolarization. In clinical trials such as BEAUTIFUL, CARVIVA HF, SHIFT, and INTENSIFY in patients with systolic left ventricular dysfunction, heart rate reduction with ivabradine brought positive outcomes...
March 28, 2018: Heart Failure Reviews
https://www.readbyqxmd.com/read/29562420/-heart-rate-control-in-chronic-heart-failure-patients-received-cardiovascular-implantable-electronic-device-therapy-effects-of-optimized-medication
#14
Y Gao, Y C Liang, H B Yu, X L Yan, B G Xu, R Liu, N Wang, G Q Xu, Z L Wang
Objective: To investigate the heart rate control situation of chronic heart failure (CHF) patients who received cardiovascular implantable electronic device (CIED) therapy, and to assess the heart rate control efficacy by optimized medication adjustment. Methods: We performed a perspective study in heart failure with reduced left ventricular ejection fraction (HFrEF) patients who received CIED according to guideline recommendations, patients were enrolled from January 2012 to January 2017. Resting heart rate (RHR) recorded by electrocardiogram after 10 minutes' rest and medication usage within 1 month were recorded at baseline...
March 24, 2018: Zhonghua Xin Xue Guan Bing za Zhi
https://www.readbyqxmd.com/read/29526184/chronic-heart-failure
#15
Frank Edelmann, Christoph Knosalla, Klaus Mörike, Christiane Muth, Peggy Prien, Stefan Störk
BACKGROUND: Chronic heart failure (CHF) is the most common reason for hospital admissions in Germany. For the National Disease Management Guideline (NDMG) on CHF, a multidisciplinary expert panel revised the chapters on drug therapy, invasive therapy, and care coordination, following the methods of evidence-based medicine. METHODS: Recommendations are based on international guideline adaptations or systematic literature search. They were developed by a multidisciplinary expert panel, approved in a formal consensus procedure, and tested in open consultation, as specified by the requirements for S3 guidelines...
February 23, 2018: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/29508636/emerging-pharmacotherapies-for-the-treatment-of-atrial-fibrillation
#16
Alessandro Capucci, Laura Cipolletta, Federico Guerra, Irene Giannini
The main aim of current research on the field of atrial fibrillation (AF) treatment is to find new antiarrhythmic drugs with less side effects. Areas covered: Dronedarone and vernakalant showed promising result in term of efficacy and safety in selected patients. Ranolazine and colchicine are obtaining a role as a potential antiarrhythmic drug. Ivabradine is used in experimental studies for the rate control of AF. Moreover, new compounds (vanoxerine, moxonidine, budiodarone) are still under investigation. Monoclonal antibodies or selective antagonist of potassium channel are under investigation for long term maintenance of sinus rhythm...
March 2018: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/29508153/efficacy-of-ivabradine-in-combination-with-beta-blockers-versus-uptitration-of-beta-blockers-in-patients-with-stable-angina-control-2-study
#17
Maria Glezer, Yuri Vasyuk, Yuri Karpov
INTRODUCTION: Heart rate (HR) reduction is an integral part of antianginal therapy, but many patients do not reach the guideline-recommended target of less than 60 bpm despite high use of beta-blockers (BB). Failure to uptitrate BB doses may be partly to blame. To explore other options for lowering HR and improving angina control, CONTROL-2 was initiated to compare the efficacy and tolerability of the combination of BBs with ivabradine versus uptitration of BBs to maximal tolerated dose, in patients with stable angina...
March 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29470374/ivabradine-for-systolic-heart-failure
#18
Courtney M Meade, Jennifer N Clements
Ivabradine works in the sinoatrial node to prolong diastolic depolarization and reduce heart rate. In patients with chronic systolic heart failure, this drug has reduced the risk of hospitalization when used in combination with other optimal pharmacotherapy.
March 2018: JAAPA: Official Journal of the American Academy of Physician Assistants
https://www.readbyqxmd.com/read/29460403/effects-of-ivabradine-on-endothelial-function-aortic-properties-and-ventricular-arterial-coupling-in-chronic-systolic-heart-failure-patients
#19
Ivano Bonadei, Edoardo Sciatti, Enrico Vizzardi, Davide Fabbricatore, Mattia Pagnoni, Laura Rossi, Valentina Carubelli, Carlo M Lombardi, Marco Metra
AIM: Heart rate (HR) is an important prognostic factor in patients affected by chronic heart failure (CHF); ivabradine has been demonstrated to significantly reduce nonfatal myocardial infarction and hospitalization rate for acute heart failure and to improve left ventricular (LV) reverse remodeling, quality of life, exercise capacity, and arterial elastance (Ea) in these patients. We aimed at evaluating the short-term effects of ivabradine on ventricular-arterial coupling (VAC), aortic stiffness, and endothelial function in stable patients with CHF...
February 20, 2018: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/29449079/cost-effectiveness-of-ivabradine-in-the-treatment-of-chronic-heart-failure
#20
Michael A Adena, Gary Hamann, Andrew P Sindone
BACKGROUND: In the Systolic Heart failure treatment with the If inhibitor Trial (SHIFT) randomised placebo-controlled trial, ivabradine was shown to reduce hospital admissions for worsening heart failure (HF) and deaths due to HF in patients with symptomatic systolic HF and an elevated resting heart rate (HR). This analysis evaluates the cost effectiveness of adding ivabradine to optimal standard HF treatment in patients with a HR≥77 bpm. METHODS: A Markov model was developed to assess the impact of ivabradine on mean survival and quality of life over a patient's lifetime (10 years)...
February 8, 2018: Heart, Lung & Circulation
keyword
keyword
76071
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"